Epidermal growth factor receptors in non-small cell lung cancer
about
Lung cancer. 1: prevention of lung cancerThe biology of DHX9 and its potential as a therapeutic targetThe role and mechanism of CRL4 E3 ubiquitin ligase in cancer and its potential therapy implicationsCombining targeted agents and hypo- and hyper-fractionated radiotherapy in NSCLCA systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity.Clinical Application of Targeted Next Generation Sequencing for Colorectal CancersCharacterization of a prostate-specific tyrosine phosphatase by mutagenesis and expression in human prostate cancer cellsPaxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancerCoexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer.Epidermal growth factor receptor (EGFR) expression in operable non-small cell lung carcinoma.Epidermal Growth Factor Receptor Cell Proliferation Signaling PathwaysEx vivo tumor culture systems for functional drug testing and therapy response predictionRapid detection of epidermal growth factor receptor mutations with multiplex PCR and primer extension in lung cancer.Construct and Compare Gene Coexpression Networks with DAPfinder and DAPview.Understanding resistance to EGFR inhibitors-impact on future treatment strategiesApoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulinv-rasH induces non-small cell phenotype, with associated growth factors and receptors, in a small cell lung cancer cell line.Recent advances in the management of squamous cell carcinoma of the head and neck.Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab.Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer.EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistryErlotinib is a viable treatment for tumors with acquired resistance to cetuximab.Targeted extracellular nanoparticles enable intracellular detection of activated epidermal growth factor receptor in living brain cancer cells.Soluble epidermal growth factor receptor (sEGFR) and carcinoembryonic antigen (CEA) concentration in patients with non-small cell lung cancer: correlation with survival after erlotinib and gefitinib treatment.Emerging drugs for head and neck cancer.Interphase cytogenetics in paraffin sections of lung tumors by non-isotopic in situ hybridization. Mapping genotype/phenotype heterogeneity.In vitro and in vivo expressions of transforming growth factor-alpha and tyrosine kinase receptors in human non-small-cell lung carcinomas.Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095.The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survivalOrgan Specific Tumor Markers: What's New?An immunohistochemical assessment of cellular proliferation markers in head and neck squamous cell cancersEffects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude miceLack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections.Tyrosine phosphorylation of 100-130 kDa proteins in lung cancer correlates with poor prognosis.Growth factors in lung cancer: possible etiologic role and clinical target.Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survivalA multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancerPhosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancerCOX-2/EGFR expression and survival among women with adenocarcinoma of the lung.EGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma.
P2860
Q24678926-D4BF382F-3F35-4E92-A3C5-423ACC1C3A93Q26749166-18F0350E-6487-43DE-9EC9-D7CAE33816C2Q26783814-D3945497-E33A-4007-B368-7809265C09DCQ26852202-EE5DA1DF-23B6-467E-A9E0-2E6DC1536D3BQ27852979-D456FC8F-3E30-45F5-94E0-654F38D42EA6Q28077199-65629515-9316-41F3-B031-ACF7DC8CDD46Q28118863-32B4B977-8C2F-4E97-9584-4DD292A0F8E8Q30542819-343AF2FF-CC41-4A9A-9309-9C8EC9D0B42FQ33206782-1E0E501E-5BFC-4BE9-A92C-EEBED0A8CA24Q33631730-5CC831F8-FECB-4FCB-9737-BAB8D4B4C747Q33737298-D4326407-60F7-4DAB-B41D-C0A217B2A760Q33827247-971BEEC6-B6A5-4E45-836B-0FAC2579524DQ33872030-BCFC94FF-A175-4149-82A6-E54CE07A9EB0Q33960783-63CFB1FB-DFD8-4246-B565-7134DCBED418Q34088424-5E5A0BDA-CCD2-4DF6-82BC-295BB95AB760Q34212131-AB9DC23B-A984-4793-B613-98B41DCF15C7Q34252335-52BB09C8-1A21-4AA4-A0D3-E8F4F00F5DD3Q34734334-579ED3BE-2D73-4299-820A-783DA6306339Q35001415-521B20DF-4419-4592-92FF-9CA1D5D72E13Q35160217-43D248EF-FD00-489E-A67E-48D04AA02440Q35164306-FFBEA287-0601-4779-828B-8A825A6088CEQ35558557-06DEE698-B881-440E-8ABF-17DD2FA2398AQ35577104-5C476D36-94FE-4EA6-9C10-5B7A50941628Q35602124-8744E59B-2C24-4B25-8C1E-D5C2D06A4C5AQ35779289-B38B4A74-08A7-4B14-BAF7-DE5F56653B93Q35832536-E792C894-E9C1-45C9-9E1B-C0CA80EB591FQ35832669-56A7C266-F286-45D3-A4F1-003F00525172Q35966914-4733AD09-4DE9-49A7-B410-2C9F8BB0CA7EQ35976186-E99B69D8-D417-48DD-8862-10F1A100A0F3Q35980584-6AFC6070-A6DD-495E-A6B5-95BEEABB571FQ35982642-CC27169C-5492-47AB-8AD6-40E943228D4BQ36080188-B9599F1A-0C73-41C2-B655-24538783C64CQ36135626-12E46E2A-8236-46DB-AD32-080C85362279Q36136019-EDCBC407-E714-42CE-80B1-845674C489E0Q36442942-268BF5C5-AE5A-49CF-8C20-E263028B3473Q36467797-7A4D29CE-D96F-49BE-9D3C-930C7BC0BA4EQ36642158-1772B61C-1DE5-4226-9802-C68903915FB9Q36717778-D90CFC70-2DFF-4DED-9661-59BB207D77AFQ36857560-5579652A-ECEA-454C-B26A-D0DD8FFBEF1DQ36962490-B674034E-82B8-4BAD-9A9C-80FC3F5C6A60
P2860
Epidermal growth factor receptors in non-small cell lung cancer
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
1987年论文
@zh
1987年论文
@zh-cn
name
Epidermal growth factor receptors in non-small cell lung cancer
@ast
Epidermal growth factor receptors in non-small cell lung cancer
@en
type
label
Epidermal growth factor receptors in non-small cell lung cancer
@ast
Epidermal growth factor receptors in non-small cell lung cancer
@en
prefLabel
Epidermal growth factor receptors in non-small cell lung cancer
@ast
Epidermal growth factor receptors in non-small cell lung cancer
@en
P2093
P2860
P356
P1476
Epidermal growth factor receptors in non-small cell lung cancer
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1987.104
P407
P577
1987-05-01T00:00:00Z